Physiologically Based Pharmacokinetic/Pharmacodynamic Model for the Treatment of Dengue Infections Applied to the Broad Spectrum Antiviral Soraphen A
- 30 August 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 4 (5) , 1499-1513
Abstract
No abstract availableKeywords
Funding Information
- Helmholtz Association
- Deutsches Zentrum f??r Infektionsforschung (TTU 09.710)
This publication has 56 references indexed in Scilit:
- Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoesProceedings of the National Academy of Sciences of the United States of America, 2013
- The Battle between Infection and Host Immune Responses of Dengue Virus and Its Implication in Dengue Disease PathogenesisThe Scientific World Journal, 2013
- Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based ConsensusPLOS Neglected Tropical Diseases, 2012
- A Randomized, Double-Blind Placebo Controlled Trial of Balapiravir, a Polymerase Inhibitor, in Adult Dengue PatientsThe Journal of Infectious Diseases, 2012
- Kinetics of Viremia and NS1 Antigenemia Are Shaped by Immune Status and Virus Serotype in Adults with DenguePLOS Neglected Tropical Diseases, 2011
- Immunological and Viral Determinants of Dengue Severity in Hospitalized Adults in Ha Noi, Viet NamPLOS Neglected Tropical Diseases, 2011
- Soraphen A, an inhibitor of acetyl CoA carboxylase activity, interferes with fatty acid elongationBiochemical Pharmacology, 2011
- Kinetics of Plasma Viremia and Soluble Nonstructural Protein 1 Concentrations in Dengue: Differential Effects According to Serotype and Immune StatusThe Journal of Infectious Diseases, 2011
- Dengue Virus Pathogenesis: an Integrated ViewClinical Microbiology Reviews, 2009
- Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease SeverityThe Journal of Infectious Diseases, 2000